{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-002113","form_type":"8-K","ticker":"DWTX","cik":"0001818844","company_name":"Dogwood Therapeutics, Inc.","filed_at":"2024-02-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.670521+00:00","generated_at":"2026-06-05T07:14:23.940857+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Virios reports FY2023 net loss $5.3M, down 57% YoY; FDA aligns on Long-COVID endpoint for IMC-2","bullets":["Net loss for FY2023 $5.3M ($0.28/share), down from $12.2M ($1.11/share) in FY2022.","R&D expenses $1.7M in FY2023 vs $8.1M in FY2022, driven by lower clinical trial costs.","Cash at Dec 31, 2023: $3.3M; expected to fund operations into Q4 2024.","FDA agreed to use fatigue as primary endpoint for IMC-2 Phase 2 in Long-COVID; initiation targeted H2 2024, pending funding.","Placebo-controlled data on valacyclovir/celecoxib for Long-COVID from Bateman Horne Center expected summer 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-002113","json":"https://secwatch.observer/filing/0001558370-24-002113.json","markdown":"https://secwatch.observer/filing/0001558370-24-002113.md","text":"https://secwatch.observer/filing/0001558370-24-002113.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818844/000155837024002113/0001558370-24-002113-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818844/000155837024002113/tmb-20240229x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T07:14:23.940857+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}